This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
What will it take? Global coalition outlines how to beat the next Disease X pandemic in 100 days
November 30, 2022; OSLO: CEPI, the Coalition for Epidemic Preparedness Innovations, has issued a report detailing how the world could deliver future pandemic-beating vaccines in 100 Days. COVID-19 vaccines were developed in record time: it took just 326 days from release of the virus’ genetic sequence to get to the authorisation of a safe and effective vaccine.

The report, published today, outlines the paradigm shift needed to speed up vaccine development even more, highlighting the crucial scientific and technological innovations that will enable us to develop new vaccines against future pandemic threats in a little more than three months. This 100 Days Mission, as embraced by the G7 and G20, would give the world a fighting shot to stop the next pandemic in its tracks. For its part, CEPI has a US$3.5 billion strategy that, over the next 5 years, will kickstart and coordinate the work necessary to achieve this mission.

Why does the world need vaccines in 100 Days?
Vaccines are our most potent weapon against infectious diseases and are at the heart of the global response to epidemic and pandemic threats. The faster safe and effective vaccines are developed and deployed, the faster a looming pandemic can be contained and controlled.

CEPI’s vision is for the world to be able to respond to the next Disease X with a new vaccine in 100 days. Achieving that goal could defuse the threat of a pathogen with pandemic potential.

If the world had delivered a vaccine in 100 days from the time when the COVID-19 viral sequences were released, a vaccine would have become available in April 2020, when there were cumulatively just over 2 million cases of COVID worldwide, rather than in December 2020, when there were almost 70 million.

Coupled with improved surveillance providing earlier detection and warning, and with swift and effective use of non-pharmaceutical interventions such as testing, contact tracing and social distancing to suppress disease transmission, delivering a vaccine in 100 days would give the world a fighting chance to extinguish the existential threat of a future pandemic virus.

"What will it take?"
CEPI’s What Will it Take report outlines 5 areas of innovation needed to make delivery of pandemic vaccines within 100 days a reality:

(1) Creating a library of prototype vaccines for representative pathogens across multiple virus families
This includes creating libraries of vaccine constructs against representative pathogens from virus families with greatest pandemic potential. Advancing the world’s experience with vaccine platforms will also be important, so that they can be used for rapid adaptation to develop vaccines against new pandemic threats.
(2) Getting clinical trials networks at the ready

Establishing global clinical trials networks with pre-established processes and protocols will be crucial. This will enable rapid generation of efficacy and safety data across a broad geographic base. These networks would be supported by a global clinical laboratory network (such as CEPI’s Centralised Lab Network) to facilitate faster data readouts.

(3) Speeding up identification of immune response markers

In response to the emergence of a novel pathogen, identification of immune markers can help to provide an early indication of vaccine efficacy prior to the traditional 14–21-day timeline taken to observe a full, immune responses. This will require further investment in research to improve our understanding of the immune response, enabled by the application of advanced data science and artificial intelligence.

(4) Establishing global capacity to make top-quality, safe, and effective new vaccines quickly

Optimising manufacturing processes for rapid initial production and subsequent scaling will be critical to responding to future pandemic threats. Establishing a global network of vaccine manufacturers in or near areas at high risk of disease outbreaks is crucial. Keeping these facilities commercially viable in inter-pandemic periods will be key to their sustainability. To ensure these manufacturing hubs can respond in a 100-day period, manufacturing capacity for multiple different vaccine platforms will need to be reserved in advance of any pandemic.

(5) Strengthening disease surveillance and global early-warning systems

Strong, active, and continuous global disease surveillance capabilities will enable faster outbreak-alert triggers, especially in lower-income regions. Harmonisation of these alert triggers, as well as viral sequence sharing, will also save vital moments in the early stages of a global response to a pandemic threat.

Richard Hatchett, CEO of CEPI, said: “The shockwaves of the COVID-19 pandemic continue to reverberate. But the scientific advances that it necessitated have now created an opportunity for the world. It has given us the means to compress vaccine development down to 100 days—a plan we at CEPI call the 100 Days Mission. If the world can achieve this, it’s possible to imagine a future in which pandemics no longer threaten our way of life. Political support for the 100 Days Mission is strong: the UK and Germany, Italy, and Indonesia have set it as a top priority in their respective G7 and G20 presidencies over the past two years. With continued political will and the right investments, the leaders of the world have an opportunity to protect their people, protect the world, and prevent future pandemics.”

Download the plan, Delivering Pandemic Vaccines in 100 Days, here.

“Post-COVID Transformation”

NAM Leadership Consortium announces formation of national commission on post-COVID transformation of the U.S. health system

National Academy of Medicine  November 30, 2022
The NAM Leadership Consortium today announced the *Emerging Fairer & Stronger from COVID-19: the National Commission on Investment Imperatives for a Healthy Nation (the Commission)*. This new initiative aims to advance transformative improvements in the U.S. health system, motivated by and based on lessons learned from deadly shortfalls experienced during the COVID-19 pandemic.

**The Commission will be a partnership enterprise, including leadership from the New England Journal of Medicine**, which will bring strong experience in communication of findings, and a coalition of locally oriented health and social service philanthropies from throughout the nation convened by Missouri Foundation for Health. This coalition will provide front-line insights for the work and will cultivate on-the-ground implementation strategies for improved health system alignment and performance among local and regional organizations. **The Commission will identify priority measures for transforming alignment across sectors to avoid the tragic shortfalls experienced acutely during the pandemic, but long present as basic health system weaknesses.**

Mark McClellan, founding Director of the Duke-Margolis Center for Health Policy at Duke University, said, “Now more than ever, we need strong collaboration toward our common interest of advancing health system effectiveness, efficiency, equity, and continuous learning. The Leadership Consortium is well-positioned to leverage stakeholder leaders from across the nation and expertise in science, informatics, incentives, and culture to provide evidence-based guidance that enables progress.”

...The Commission will examine...three core cross-sectoral challenges: health system fragmentation, misaligned incentives, and structural inequities, describing their characteristics and identifying strategic actions and policies to remedy them.

**The Commission will be comprised of independent thought leaders** collectively charged with overseeing the five expert-led work streams that aim to transform health system alignment and performance while also advancing social justice:

- **Person & community motivated**: establishing personal and community health goals and priorities as the core design features of health system structure and function
- **Equity & fairness**: developing and fostering strategies for conversations, understandings, and actions that bridge groups and cultures
- **Health financing**: focusing payments and accountability on improving individual and community health outcomes
- **Data & digital health**: accelerating digitally-enabled health data security, validation, sharing, analysis, and action to drive health improvement and continuous learning
- **Capital flow**: investment strategies oriented to advancing the nation’s health and economic well-being

...Each work stream will undertake two tasks:

1) producing a qualitative and quantitative analysis of the potential health and economic gains from achieving the work stream’s goal and the consequences of inaction, and
2) conducting a review of policy and cultural changes needed to realize the transformative aim.

Commissioners will then develop a composite report summarizing the findings across the work streams, highlighting the potential opportunities and consequences, and recommending the priority actions for aligning strategies across stakeholders...
Perspective

It Ain’t Over Till It’s Over…but It’s Never Over — Emerging and Reemerging Infectious Diseases

A.S. Fauci

As I prepare to step down from my dual positions at the National Institute of Allergy and Infectious Diseases (NIAID), where I have been a physician-scientist for 54 years and the director for 38 years, a bit of reflection is inevitable. As I think back over my career, what stands out most is the striking evolution of the field of infectious diseases and the changing perception of the importance and relevance of the field by both the academic community and the public.

I completed my residency training in internal medicine in 1968 and decided to undertake a 3-year combined fellowship in infectious diseases and clinical immunology at NIAID. Unbeknownst to me as a young physician, certain scholars and pundits in the 1960s were opining that with the advent of highly effective vaccines for many childhood diseases and a growing array of antibiotics, the threat of infectious diseases — and perhaps, with it, the need for infectious-disease specialists — was fast disappearing. Despite my passion for the field I was entering, I might have reconsidered my choice of a subspecialty had I known of this skepticism about the discipline’s future. Of course, at the time, malaria, tuberculosis, and other diseases of low- and middle-income countries were killing millions of people per year. Oblivious to this inherent contradiction, I happily pursued my clinical and research interests in host defenses and infectious diseases.

When I was several years out of my fellowship, I was somewhat taken aback when Dr. Robert Petersdorf, an icon in the field of infectious diseases, published a provocative article in the Journal suggesting that infectious diseases as a subspecialty of internal medicine was fading into oblivion. In an article entitled “The Doctors’ Dilemma,” he wrote regarding the number of young physicians entering training in the various internal medicine subspecialties, “Even with my great personal loyalties to infectious disease, I cannot conceive a need for 309 more infectious-disease experts unless they spend their time culturing each other.”

Of course, we all aspire to be part of a dynamic field. Was my chosen field now static? Dr. Petersdorf (who would become my friend and part-time mentor as we and others coedited Harrison’s Principles of Internal Medicine) gave voice to a common viewpoint that lacked a full appreciation of the truly dynamic nature of infectious diseases, especially regarding the potential for newly emerging and
reemerging infections. In the 1960s and 1970s, most physicians were aware of the possibility of pandemics, in light of the familiar precedent of the historic influenza pandemic of 1918, as well as the more recent influenza pandemics of 1957 and 1968. However, the emergence of a truly new infectious disease that could dramatically affect society was still a purely hypothetical concept.

That all changed in the summer of 1981 with the recognition of the first cases of what would become known as AIDS. The global impact of this disease is staggering: since the start of the pandemic, more than 84 million people have been infected with HIV, the virus that causes AIDS, of whom 40 million have died. In 2021 alone, 650,000 people died from AIDS-related conditions, and 1.5 million were newly infected. Today, more than 38 million people are living with HIV.

Although a safe and effective HIV vaccine has not yet been developed, scientific advances led to the development of highly effective antiretroviral drugs that have transformed HIV infection from an almost-always-fatal disease to a manageable chronic disease associated with a nearly normal life expectancy. Given the lack of global equity in the accessibility of these lifesaving drugs, HIV/AIDS continues, exacting a terrible toll in morbidity and mortality, 41 years after it was first recognized.

If there is any silver lining to the emergence of HIV/AIDS, it is that the disease sharply increased interest in infectious diseases among young people entering the field of medicine. Indeed, with the emergence of HIV/AIDS, we sorely needed those 309 infectious-disease trainees that Dr. Petersdorf was concerned about — and many more. To his credit, years after his article was published, Dr. Petersdorf readily admitted that he had not fully appreciated the potential impact of emerging infections and became something of a cheerleader for young physicians to pursue careers in infectious diseases and specifically in HIV/AIDS practice and research.

Selected Landmark Events in Infectious-Disease Emergence Leading up to and during the Author’s Four-Decade Tenure as NIAID Director.

Of course, the threat and reality of emerging infections did not stop with HIV/AIDS. During my tenure as NIAID director, we were challenged with the emergence or reemergence of numerous infectious
diseases with varying degrees of regional or global impact (see timeline). Included among these were the first known human cases of H5N1 and H7N9 influenza; the first pandemic of the 21st century (in 2009) caused by H1N1 influenza; multiple outbreaks of Ebola in Africa; Zika in the Americas; severe acute respiratory syndrome (SARS) caused by a novel coronavirus; Middle East respiratory syndrome (MERS) caused by another emergent coronavirus; and of course Covid-19, the loudest wake-up call in more than a century to our vulnerability to outbreaks of emerging infectious diseases.

The devastation that Covid-19 has inflicted globally is truly historic and highlights the world’s overall lack of public health preparedness for an outbreak of this magnitude. One highly successful element of the response to Covid-19, however, was the rapid development — enabled by years of investment in basic and applied research — of highly adaptable vaccine platforms such as mRNA (among others) and the use of structural biology tools to design vaccine immunogens. The unprecedented speed with which safe and highly effective Covid-19 vaccines were developed, proven effective, and distributed resulted in millions of lives saved. Over the years, many subspecialties of medicine have benefited greatly from breathtaking technological advances. The same can now be said of the field of infectious diseases, particularly with the tools we now have for responding to emerging infectious diseases, such as the rapid and high-throughput sequencing of viral genomes; the development of rapid, highly specific multiplex diagnostics; and the use of structure-based immunogen design combined with novel platforms for vaccines.

If anyone had any doubt about the dynamic nature of infectious diseases and, by extension, the discipline of infectious diseases, our experience over the four decades since the recognition of AIDS should have completely dispelled such skepticism. Today, there is no reason to believe that the threat of emerging infections will diminish, since their underlying causes are present and most likely increasing. The emergence of new infections and the reemergence of old ones are largely the result of human interactions with and encroachment on nature. As human societies expand in a progressively interconnected world and the human–animal interface is perturbed, opportunities are created, often aided by climate changes, for unstable infectious agents to emerge, jump species, and in some cases adapt to spread among humans.

An inevitable conclusion of my reflections on the evolution of the field of infectious diseases is that the pundits of years ago were incorrect and that the discipline is certainly not static; it is truly dynamic. In addition to the obvious need to continue to improve on our capabilities for dealing with established infectious diseases such as malaria and tuberculosis, among others, it is now clear that emerging infectious diseases are truly a perpetual challenge. As one of my favorite pundits, Yogi Berra, once said, “It ain’t over till it’s over.” Clearly, we can now extend that axiom: when it comes to emerging infectious diseases, it’s never over. As infectious-disease specialists, we must be perpetually prepared and able to respond to the perpetual challenge.

---

**PHEIC**

**Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

Weekly Epidemiological and Operational updates
Last update: 03 Dec 2022

Confirmed cases :: 640 395 651
Confirmed deaths :: 6 618 579
Vaccine doses administered: 13 042 112 489


Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 27 November 2022**

Weekly epidemiological update on COVID-19 - 30 November 2022
Overview
Globally, the number of new weekly cases remained stable (+2%) during the week of 21 to 27 November 2022, as compared to the previous week, with just under 2.7 million new cases reported. The number of new weekly deaths decreased by 5%, as compared to the previous week, with about 8400 fatalities reported. As of 27 November 2022, 637 million confirmed cases and 6.6 million deaths have been reported globally...

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 03 Dec 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]
Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 03 Dec 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

COVID Vaccines – OCHA:: HDX
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
NOV 05 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 121M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.0B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 390M
Other Delivered (Number of Doses): 420M
Total Delivered (Number of Doses): 800M
Total Administered (Number of Doses): 530M

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 03 Dec 2022: https://data.covid19taskforce.com/data

The global view below is complemented by country-specific dashboards here.

---

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
Our World in Data

**Coronavirus (COVID-19) Vaccinations**  [Accessed 03 Dec 2022]

:: **68.5%** of the world population has received at least one dose of a COVID-19 vaccine.
:: **13.01 billion doses** have been administered globally, and **2.51 million** are now administered each day.
:: **24.6%** of people in low-income countries have received at least one dose.

**Global COVID-19 Access Tracker**
[https://www.covid19globaltracker.org/](https://www.covid19globaltracker.org/)
HHS

News

Biden Harris Administration Supports the World Health Organization Renaming of Monkeypox to mpox
November 28, 2022 | News Release

FDA

Press Announcements
No new digest content identified.

European Medicines Agency

News & Press Releases
No new digest content identified.

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News  [Selected]

Joint EC, WHO and ECDC statement: Influenza season epidemic kicks off early in Europe as concerns over RSV rise and COVID-19 is still a threat
News story - 1 Dec 2022

WHO/Europe and ECDC report reveals increasing numbers living with undiagnosed HIV in the Region
Press release - 30 Nov 2022

Ebola outbreak in Uganda, as of 22 November 2022
Epidemiological update - 25 Nov 2022

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Encountered at inquiry: "The Web Page is Under Maintenance!!!"

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/
Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations.]

China’s Xi unwilling to accept vaccines despite protests, U.S. official says
Reuters
1 hour ago

Beijing, Shenzhen loosen more COVID curbs as China fine-tunes policy
Reuters
9 hours ago

PHEIC
Mpox
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

1 December 2022
Multi-country outbreak of mpox, External situation report #11 - 1 December 2022
Highlights
:: Following a series of consultations with global experts, WHO will begin using the term “mpox” as the
preferred name for the disease of monkeypox. Both names will be used simultaneously for one year while “monkeypox” is phased out. During the week of 21 to 27 November 2022, the number of mpox cases reported globally continued to decline.

:: In the week commencing 21 November, the Eastern Mediterranean Region has reported six new cases after five consecutive weeks without cases. These are retrospective reports of cases diagnosed between 1 October and 25 November 2022.
:: Since the last situation report published on 16 November, 1696 new cases (2.1% increase in total cases) and five new deaths have been reported.
:: Since the beginning of the outbreak, a high prevalence of HIV infection (52%; 14 573/28 006) has been reported among cases with known HIV status.
:: The proportion of cases among females has been gradually increasing since the beginning of the outbreak, reaching 6.7% as of 20 November 2022

---

**PHEIC**

**Polio**

**Polio this week as of 30 November 2022 - GPEI**

:: In Indonesia, following confirmation last week of VDPV2 isolated from an AFP case (7-year old child) with onset of paralysis on 9 October, from Aceh province, circulating of this strain has been confirmed following isolation of the virus from three healthy community contacts. See ‘Indonesia’ section below,
:: At a WHO Member State Information Session on 16th November, regional and programme representatives set out the actions being taken in 2023 to step up polio transition efforts towards strengthening health systems, bolstering immunization and disease surveillance, and protecting against polio outbreaks. Particular focus is on the development of a global vision for polio transition, supported by tailored regional action plans and a strengthened monitoring and evaluation framework, building on successes and lessons learned so far.
:: nOPV2 rollout: Approximately 525 million doses of nOPV2 have been administered across 25 countries under its WHO Emergency Use Listing (EUL). An additional 15 countries have met the requirements for nOPV2 use in the event of an outbreak. For more information on nOPV2, visit: www.polioeradication.org/nOPV2.

Summary of new polioviruses this week:
- Afghanistan: two WPV1 positive environmental samples
- DR Congo: one cVDPV1 case
- Indonesia: one cVDPV2 case
- Nigeria: five cVDPV2 positive environmental samples
- Yemen: four cVDPV2 cases

---

**UN OCHA – Current Emergencies**

Current Corporate Emergencies

**Afghanistan**
No new digest content identified.

**Northern Ethiopia**  
No new digest content identified.

**Somalia**  
No new digest content identified.

**Ukraine**  
Highlights Last Updated: 29 Nov 2022

WHO & Regional Offices [to 03 Dec 2022]  
https://www.who.int/news  
Selected News/Announcements/Statements  
2 December 2022  
News release  
**The European Commission and WHO extend their strategic cooperation to deliver better health for all**

1 December 2022  
News release  
**WHO calls on the global community to equalize the HIV response**

1 December 2022  
Departmental news  
**Equalize – addressing inequalities to End TB and AIDS!**

1 December 2022  
News release  
**WHO and the EU renew partnership for Universal Health Coverage**

30 November 2022  
Departmental news  
**Moving forward on building equitable access to vaccines, WHO successfully close the third Virtual cGMP Training Marathon for Vaccine Manufacturing**

29 November 2022  
Departmental news  
**Republic of Korea achieves the highest WHO level for regulation of medicines and vaccines**

28 November 2022  
News release  
**WHO recommends new name for monkeypox disease**
Carissa F. Etienne on PAHO’s 120th Anniversary: solidarity can help build a healthier and more hopeful future for all
Washington, DC, December 2, 2022 (PAHO) - The Director of the Pan American Health Organization (PAHO), Carissa F. Etienne, released a message today to mark the Organization’s 120th Anniversary. "For 120 years, the Americas have relied on cooperation because we have understood that our health, our security and our prosperity are interdependent;"

PAHO celebrates 120 years promoting health in the Americas
Washington D.C. 1 December 2022 (PAHO) – Tomorrow, the Pan American Health Organization (PAHO) marks its Anniversary as the world’s oldest international public health agency, celebrating 12 decades of work promoting health and wellbeing throughout the region of the Americas. On this day in 1902, 11 countries came together at the First General...

Adoption of front-of-pack nutrition warnings can help decrease obesity, cardiovascular disease, type-2 diabetes and some cancers in the Americas
Study finds that the increased use of government-implemented warning labels can help reducing poor-nutrition related diseases RENO, Nev. — The adoption of best practice front-of-pack nutrition labeling in more countries of Americas can help reduce poor-nutrition related non-communicable diseases (NCDs) such as cardiovascular disease, type-2...

Addressing inequalities key to ending AIDS: PAHO
Latin America and the Caribbean must expand and accelerate access to HIV diagnosis, prevention, and treatment to reduce new infections Washington, DC, November 30, 2022 (PAHO) - The Pan American Health Organization is marking World AIDS Day (1 December) with a call for countries to address the inequalities that prevent progress towards ending...

PAHO calls for improved health service response to violence against women
New report highlights that, although 83% of PAHO Member States have included violence against women in their health plans or policies, only half recommend essential first-line support. Washington, D.C., November 30, 2022 (PAHO) – The Pan American Health Organization (PAHO) this week launched a new report assessing the status of health sector...

Regional Forum for Primary Health Care-Oriented Health Systems launched to strengthen implementation-focused learning and cooperation

PAHO calls for improved health service response to violence against women
New report highlights that, although 83% of PAHO Member States have included violence against women in their health plans or policies, only half recommend essential first-line support. Washington, D.C., November 30, 2022 (PAHO) – The Pan American Health Organization (PAHO) this week launched a new report assessing the status of health sector...
Joint statement - Influenza season epidemic kicks off early in Europe as concerns over RSV rise and COVID-19 is still a threat

WHO Western Pacific Region
:: 29 November 2022 | News release
Republic of Korea achieves the highest WHO level for regulation of medicines and vaccines

:::

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

28 November 2022 | Dengue - Bangladesh
As of 20 November 2022, a total of 52,807 laboratory-confirmed dengue cases and 230 related deaths have been reported by the Ministry of Health & Family Welfare of Bangladesh since 1 January 2022 with a case fatality rate (CFR) of 0.44%. Dengue is endemic in Bangladesh however a surge of cases started in June 2022. Currently, all eight divisions in the country are reporting cases and deaths. This is the second-largest outbreak since 2000, with the largest having occurred in 2019. The current dengue outbreak is unusual in its scale and seasonality...

:::

New WHO Publications
https://www.who.int/publications/i
Selected Titles
2 December 2022
WHO Ukraine crisis response: October 2022 bulletin

2 December 2022
Global report on health equity for persons with disabilities

2 December 2022
Global report on health equity for persons with disabilities: executive summary

28 November 2022
First meeting of the WHO Strategic and Technical Advisory Group working group on access to safe, efficacious and quality-assured health products for neglected tropical diseases. Virtual meeting, 15–16 September 2022

27 November 2022
Global clinical data platform: Ebola virus disease case report form (CRF): module 3, 29 November 2022

:::::
COVID-19 disruptions in HIV testing and prevention highlight need for innovation and investment before the next public health emergency

December 1, 2022  The nation’s ability to prevent HIV was dealt a hard blow early in the COVID-19 pandemic, according to a new CDC analysis published today, on World AIDS Day: Putting Ourselves to the Test: Achieving Equity to End HIV. A rapid...

CDC planning wastewater testing for polio in select communities

November 30, 2022  The U.S. Centers for Disease Control and Prevention (CDC) will strategically expand wastewater testing for poliovirus in select jurisdictions across the country.

CDC Awards More Than $3 Billion to Improve U.S. Public Health Workforce and Infrastructure

November 29, 2022

::::::

ACIP Meetings

Next ACIP Meeting

No 2022 meetings identified.

::::::

MMWR Weekly: Current Volume (71)

December 2, 2022 / No. 48

PDF of this issue

- HIV Services and Outcomes During the COVID-19 Pandemic — United States, 2019–2021
- SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022
- Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
- Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022

::::::

Coronavirus Disease 2019 (COVID-19)- CDC

Announcements/reports/data summaries.

::::::

Africa CDC  [to 03 Dec 2022]

http://www.africacdc.org/

News
The Republic of Korea to Donate First Batch of Mpox Vaccine to Africa
29 November 2022

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 03 Dec 2022]
http://en.nhc.gov.cn/
News
Dec 3: Daily briefing on novel coronavirus cases in China
On Dec 2, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 3,988 new cases of confirmed infections.

National Medical Products Administration – PRC [to 03 Dec 2022]
http://english.nmpa.gov.cn/
Chinese mainland reports 4,233 new local confirmed COVID-19 cases
2022-12-02
The Chinese mainland on Thursday reported 4,233 locally transmitted confirmed COVID-19 cases, the National Health Commission said Friday.

CCDC Weekly Reports: Current Volume (4)
2022-12-02 / No. 48  CERVICAL CANCER PREVENTION AND CONTROL ISSUE
View PDF of this issue
- Foreword: Accelerating Cervical Cancer Prevention and Control in China to Achieve Cervical Cancer Elimination Strategy Objectives
- Preplanned Studies: Cervical Cancer Screening Coverage — China, 2018–2019
- Preplanned Studies: Prevalence of High-Risk Human Papillomavirus by Subtypes Among Rural Women Aged 35–64 Years — Guangzhou City, Guangdong Province, China, 2019–2021

Organization Announcements

Paul G. Allen Frontiers Group [to 03 Dec 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.
Statement from Gates Foundation CEO Mark Suzman: Why we need digital infrastructure

Press release  Dec 01, 2022

How we think about infrastructure for development is changing. Beyond roads and bridges, we also need digital public infrastructure (DPI) that can support a range of applications, from mobile banking and social welfare to disease surveillance.

DPI, which is often based on open-source software, has significant potential for accelerating improvements in health and economic welfare. We saw this during the COVID-19 pandemic—countries with digital infrastructure were able to quickly send stimulus payments to their most vulnerable populations...

Bill & Melinda Gates Medical Research Institute

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people

CEPI – Coalition for Epidemic Preparedness Innovations

What will it take? Global coalition outlines how to beat the next Disease X pandemic in 100 days

CEPI’s What Will it Take report outlines 5 areas of innovation needed to make delivery of pandemic vaccines within 100 days a reality

25 Nov 2022
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 03 Dec 2022]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 03 Dec 2022]
https://dukeghic.org/
Our Blog
Global Preparedness Requires More Than Just Additional Funding
November 28, 2022 By Nellie Bristol
COVID GAP The West African Ebola outbreak of 2014-2016 brought a surge of national and international attention to epidemic and pandemic preparedness including revamped or new country level capacity assessment tools. The assessments, including

EDCTP [to 03 Dec 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
01 December 2022
World AIDS Day 2022: funding to end inequality

Emory Vaccine Center [to 03 Dec 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 03 Dec 2022]
http://www.euvgaccine.eu/
Latest News, Events
No new digest content identified

Evidence Aid [to 03 Dec 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/

**Ethical guidance for disaster response**
Added December 2, 2022

**Preventing needle injuries in healthcare workers**
Added December 1, 2022

**Mental health of migrants who were exposed to armed conflict before migration**
Added November 30, 2022

**Non-communicable disease interventions for women and children in conflict settings**
Added November 29, 2022

**Frameworks for incident classification in emergency departments**
Added November 28, 2022

**Fondation Merieux** [to 03 Dec 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

**Gavi** [to 03 Dec 2022]
https://www.gavi.org/
News Releases
No new digest content identified.

**GHIT Fund** [to 03 Dec 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

**Global Fund** [to 03 Dec 2022]
News & Stories
30 November 2022
The Global Fund Commits to Over US$21.9 Million in Emergency Funding for Families Living Through Climate Crises in Pakistan and Somalia
The Global Fund to Fight AIDS, Tuberculosis and Malaria has committed US$20 million to Pakistan and US$1.9 million to Somalia in emergency funding to support the health systems faced with climate change disasters. Massive flooding in Pakistan has led...

28 November 2022
India Makes Strong Commitment to Global Fund

The Government of India has announced an increased commitment of US$25 million to the Global Fund for the next three years, highlighting India’s leadership in global efforts to end AIDS, TB and malaria and to build stronger health systems.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 03 Dec 2022]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 03 Dec 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 03 Dec 2022]
https://www.hhmi.org/news
Press Room
•
Institute  Nov 30 2022
Together, 104 Schools Pursue Inclusive Undergraduate Science Education
104 schools are receiving six-year grants as part of HHMI’s Inclusive Excellence 3 (IE3) initiative. IE3 challenges US colleges and universities to substantially and sustainably build capacity for student belonging, especially for those who have been historically excluded from the sciences.

Human Vaccines Project [to 03 Dec 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI [to 03 Dec 2022]
https://www.iavi.org/
Latest News
December 2, 2022
Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach
Scripps Research, IAVI, Fred Hutch, VRC and other collaborators publish study data in Science, helping validate novel vaccination strategy.
...In a paper published in Science on December 2, 2022, the scientists reveal critical new insights into their novel vaccine strategy, which involves a stepwise approach to producing antibodies capable of targeting a wide range of HIV variants...
ICRC  [to 015 Oct 2022]
What’s New  [Selected]
Humanitarian needs to deepen in dozens of conflict zones as world’s attention wanes
   Humanitarian needs in dozens of countries from Yemen to Somalia, Afghanistan and the Democratic Republic of Congo are rising, a pattern that the ICRC expects to continue in 2023.
29-11-2022 | News release

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 03 Dec 2022]
Press Releases [Selected]
No new digest content identified.

Institut Pasteur  [to 03 Dec 2022]
Press Documents
No new digest content identified.

ISC / International Science Council  [to 03 Dec 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Current
News
Ten key messages for the Convention on Biological Diversity
02.12.2022

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
Funding Opportunity from IUIS and FOCIS for Young Immunologists from the Developing World
December 1, 2022  Gender Equality Committee (GEC)

IVAC  [to 03 Dec 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
VIRA Chatbot Competition Awarded to Three U.S. Health Departments
December 2022
Health departments will use custom AI chatbots to address COVID-19 misinformation
Washington, DC—The National Association of County and City Health Officials (NACCHO) has announced the first three winners of the VIRA X NACCHO competition. These selected health departments will receive a customized version of the Vaccine Information Resource Assistant [...]

IVI  [to 03 Dec 2022]
http://www.ivi.int/
IVI News & Announcements
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study
Published in Clinical Infectious Diseases
- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo
- Results indicate that vaccination with SCB-2019 can potentially help control the spread of SARS-CoV-2 within communities through the reduction of transmission to household contacts and through previously demonstrated efficacy against SARS-CoV-2
- SCB-2019 is among the first COVID-19 vaccines to demonstrate ability to significantly reduce SARS-CoV-2 transmission prospectively in a clinical study to date
SHANGHAI, China and SEOUL, Republic of Korea, November 30, 2022

Johns Hopkins Center for Health Security  [to 03 Dec 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
Center for Health Security Experts Attend Biological and Toxin Weapons Convention (BWC) 9th Review Conference, Urge Endorsement of Tianjin Biosecurity Guidelines
November 30, 2022

MSF/Médecins Sans Frontières  [to 03 Dec 2022]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

National Academy of Medicine - USA  [to 03 Dec 2022]
https://nam.edu/programs/
NAM Leadership Consortium announces formation of national commission on post-COVID transformation of the U.S. health system
November 30, 2022
The NAM Leadership Consortium today announced the Emerging Fairer & Stronger from COVID-19: the National Commission on Investment Imperatives for a Healthy Nation (the Commission). This new initiative aims to [...]

National Academy of Sciences - USA [to 03 Dec 2022]

Third International Summit on Human Genome Editing to Take Place in London March 6-8 2023
November 29, 2022
Registration is now open for the Third International Summit on Human Genome Editing to be held March 6-8 2023 in London. The three-day summit is being organized by the Royal Society and U.K. Academy of Medical Sciences the U.S. National Academy of Sciences and National Academy of Medicine and the World Academy of Sciences

New Report Identifies Action Steps and Research to Accelerate Progress on Sustainable Development Goals
November 28, 2022
A new report identifies research and possible action steps that governments nongovernmental and philanthropic organizations universities and the private sector can take to operationalize the United Nations Sustainable Development Goals.

National Vaccine Program Office - U.S. HHS [to 03 Dec 2022]
https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 03 Dec 2022]
http://www.nih.gov/

News Releases
Dr. Fauci reflects on the perpetual challenge of infectious diseases
November 28, 2022 — He has directed NIAID since 1984

PATH [to 03 Dec 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Rockefeller Foundation [to 03 Dec 2022]
Sabin Vaccine Institute [to 03 Dec 2022]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS [to 03 Dec 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

UNICEF [to 03 Dec 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release 28 November 2022
HIV prevention and treatment progress for children, adolescents, and pregnant women nearly flat over past few years – UNICEF
NEW YORK, 28 November 2022 – Around 110,000 children and adolescents (0-19 years) died from AIDS-related causes during 2021, according to the latest UNICEF global snapshot on children and HIV and AIDS. Meanwhile, another 310,000 were newly infected, bringing the total number of young people living with HIV to 2.7 million. Ahead of World AIDS Day,...

Unitaid [to 03 Dec 2022]
https://unitaid.org/
Featured News
30 November 2022
Unitaid highlights gender gaps and calls for innovative strategies to reach all people at risk ahead of World AIDS Day

Vaccine Equity Cooperative [nee Initiative] [to 03 Dec 2022]
https://vaccineequitycooperative.org/news/
News
Dec 02, 2022
Media: Community health groups that played crucial role during Covid-19 pandemic say they’re being left out of government funding
Venus Ginés and Denise Octavia Smith discuss the lack of federal investment towards grassroots organizations
Vaccination Acceptance & Demand Initiative [Sabin] [to 03 Dec 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 03 Dec 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 03 Dec 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 03 Dec 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
Explainer
Advances in fighting malaria: from bed nets to the first-ever vaccine
27 November 2022

The Wistar Institute [to 03 Dec 2022]
Media
Press Release Dec. 1, 2022
Wistar’s Hubert J.P. Schoemaker Education and Training Center Receives National Science Foundation REU Grant
Funding supports a new summer training program for undergrads from underrepresented sectors to support increased opportunities in the biomedical research field.

WFPHA: World Federation of Public Health Associations [to 03 Dec 2022]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

World Bank [to 015 Oct 2022]
All News
WASHINGTON, December 1, 2022 - Two years of pandemic have highlighted the vulnerability and isolation of populations without electricity and have prompted countries to increase their focus on energy access...

Date: December 01, 2022 Type: Press Release

World Bank: How Central Asian Countries Can Prevent Future Pandemics

This interview was originally published in Russian by Forbes Kazakhstan on November 29, 2022 Martien van Nieuwkoop, the World Bank’s Global Director for the Agriculture and Food Global Practice, visited...

Date: November 30, 2022 Type: Opinion

World Customs Organization – WCO [to 015 Oct 2022]
http://www.wcoomd.org/
Latest News
No new digest content identified.

World Medical Association [WMA] [to 03 Dec 2022]
Press Releases
No new digest content identified.

World Organisation for Animal Health (OIE) [to 03 Dec 2022]
https://www.oie.int/en/
Press Releases, Statements
No new digest content identified.

WTO - World Trade Organisation [to03 Dec 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
No new digest content identified.

::::::

ARM [Alliance for Regenerative Medicine] [to 03 Dec 2022]
Selected Press Releases
No new digest content identified.

BIO [to 03 Dec 2022]
Press Releases
No new digest content identified.
### DCVMN – Developing Country Vaccine Manufacturers Network

[to 03 Dec 2022]

http://www.dcvmn.org/

News; Upcoming events

No new digest content identified.

### ICBA – International Council of Biotechnology Associations

[to 03 Dec 2022]

https://internationalbiotech.org/news/

News

No new digest content identified.

### IFPMA

[to 03 Dec 2022]

http://www.ifpma.org/resources/news-releases/

Selected Press Releases, Statements, Publications

**Proposals from the pharmaceutical Industry for the G7 Hiroshima Summit Health Agenda**

30 November 2022

The Japanese Pharmaceutical Manufacturers Association (JPMA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) jointly submitted the “Proposals from the Pharmaceutical Industry for the G7 Hiroshima Summit Health Agenda” to the Prime Minister, Minister of Health, Labor and Welfare, Minister of Finance, and Minister of Foreign Affairs. Download the letter below.

» JPMA IFPMA letter G7

**Survey shows an improvement in research-based pharmaceutical industry reputation with people valuing pharma innovation and the benefits it brings to society**

30 November 2022

...The survey found that:

:: 68% agree that research-based pharmaceutical companies have a leading role in advancing new technologies, such as better, more effective medicines or vaccines that are useful in response to the COVID-19 pandemic

:: 62% agree that research-based pharmaceutical companies are doing all they can to develop solutions to COVID-19

:: 67% agree that research-based pharmaceutical companies have a leading role in the development of new technologies that could be useful in response to future public health crises, such as pandemics.

### International Alliance of Patients’ Organizations – IAPO

[to 03 Dec 2022]

https://www.iapo.org.uk/news/topic/6

Press and media [Selected]

No new digest content identified.

### International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

No new digest content identified.
PhRMA  [to 03 Dec 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

::::::
::::::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases  -  No new digest announcements identified

Bharat Biotech
Press Releases
Nov 28: **iNCOVACC® World's first Intranasal Vaccine to receive both Primary series and Heterologous booster approval**

BioCubaFarma – Cuba
Últimas Noticias  -  Website not responding at inquiry

Biological E
News  -  No new digest announcements identified

BioNTech
Press Releases  -  No new digest announcements identified

Boehringer
Press Releases  -  No new digest announcements identified

CanSinoBIO
News  -  Website not responding at inquiry

CIGB
Latest News  -  No new digest announcements identified

Cinnagen
Recent News  -  No new digest announcements identified

Clover Biopharmaceuticals - China
News
Nov 30,2022  **Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases**

Curevac  [Bayer Ag – Germany]
News  -  No new digest announcements identified
Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media - No new digest announcements identified

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Medicago
Media - No new digest announcements identified

Merck
News releases - No new digest announcements identified

Moderna
Press Releases - No new digest announcements identified

Nanogen
News - No new digest announcements identified

Novartis
News - No new digest announcements identified

Novavax
Press Releases
Nov 29, 2022
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

Pfizer
Recent Press Releases
12.01.2022 Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases -- No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified
Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
SINOVAC Quadrivalent Influenza Vaccine Authorized for Commercialization in the Dominican Republic
2022/11/29

SK Biosciences
Press Releases - No new digest announcements identified

Takeda
Newsroom - No new digest announcements identified

Valneva
Press Releases
December 1, 2022
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

Vector State Research Centre of Viralogy and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
**Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

---

**AJOB Empirical Bioethics**

Volume 13, 2022 Issue 4
[Reviewed earlier]

[https://www.tandfonline.com/toc/uabr21/current](https://www.tandfonline.com/toc/uabr21/current)

**AMA Journal of Ethics**

Volume 24, Number 12: E1107-1182

**With Stillness and Solidarity**

This issue considers stillness and solidarity as necessary to orientating oneself to health care practice and professionalism. These two are both actions and virtues, which enable students’ and clinicians’ transformation from bystanders to upstanders. Stillness is conceived herein as intentional discipline applied to creating deliberate, restorative spatial and temporal interruption from day-to-day demands in order to nourish the moral motivational generosity needed to care well for patients and to be good colleagues. Solidarity is conceived herein as requiring deliberate nourishing in health professions education and work environments, such that slowing down, a necessary precedent set of actions to becoming still, can be robustly achieved and engaged. This issue explores ways in which solidarity can be considered less as a set of political actions of single individuals and more as a collective organizational and professional capacity for responding with care to both our unique and common vulnerabilities.

*From the Editor* Dec 2022

**With Stillness and Solidarity**
Jeremy Weleff, DO

In recent years, unrest, protests, and uprisings about class and race conflict have compelled many health professionals to question and to stand in solidarity with communities.

*Case and Commentary* Dec 2022

**How Should Clinicians Own Their Roles as Past and Present Exacerbators of Health Inequity and as Present and Future Contributors to Health Equity?**
Lisa M. Lee, PhD, MA, MS and Anita L. Allen, JD, PhD

To improve health outcomes, clinicians must move quickly yet operate slowly enough to center empathy in practice.

---

**American Journal of Infection Control**
American Journal of Preventive Medicine
December 2022  Volume 63  Issue 6  p875-1064
https://www.ajpmonline.org/current
Research Articles
Geographic Heterogeneity in Behavioral and Social Drivers of COVID-19 Vaccination
Nina B. Masters, et al.
Published online: July 19, 2022
p883-893

Multiscale Dimensions of Spatial Process: COVID-19 Fully Vaccinated Rates in U.S. Counties
Tse-Chuan Yang, Stephen A. Matthews, Feinuo Sun
Published online: July 06, 2022
p954-961

Current Issues
Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable
Eli Y. Adashi, Philip A. Gruppuso
Published online: July 10, 2022
p1062-1063

American Journal of Public Health
December 2022  112(12)
http://ajph.aphapublications.org/toc/ajph/current
EDITORIALS
Effect of Masking to Prevent COVID-19 Transmission in Schools and the Responsibility of States to Protect Public Health
Chloe A. Teasdale and Sasha A. Fleary

PERSPECTIVES
Communities, Mistrust, and Implementation: Addressing a Large Gap in the National Strategy for COVID-19 and Future Pandemics
Infections, Prevention, Immunization/Vaccines, COVID-19, Public Health Practice, Community Health, Other Infections, Editorial
Howard Hu, Frank Gilliland and Lourdes Baezconde-Garbanati
NOTES FROM THE FIELD

Community-Based COVID-19 Vaccine Clinics in Medically Underserved Neighborhoods to Improve Access and Equity, Philadelphia, 2021–2022
Health Service Delivery, Immunization/Vaccines, COVID-19, Community Health, Socioeconomic Factors, Race/Ethnicity
Heather Klusaritz, Emily Paterson, Courtney Summers, Nida Al-Ramahi, Nawar Naseer, Helena Jeudin, Yuhnis Sydor, Maurice Enoch, Nieemah Dollard, Kevin D. Young, Neda Khan, Jeffrey Henne, Anna Doubeni, Nishaminy Kasbekar, Yevgeniy Gitelman, Patrick J. Brennan, Kent Bream, Carolyn C. Cannuscio, Richard C. Wender and Rachel Feuerstein-Simon

THE CRUEL PUBLIC HEALTH CONSEQUENCES OF ANTI-IMMIGRANT RHETORIC

EDITORIALS

State-Level Legislation During the COVID-19 Pandemic to Offset the Exclusion of Undocumented Immigrants From Federal Relief Efforts
Immigration, Health Policy, Editorial
Arturo Vargas Bustamante, Joseph Nwadiuko and Alexander N. Ortega

Chronic Disease, Other Race/Ethnicity, COVID-19, Injury/Emergency Care/Violence, Socioeconomic Factors, Other Chronic Disease, Race/Ethnicity, Epidemiology
Megan Todd and Annaka Scheeres

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 5 (Nov 2022)

Perspective Piece

Chagas Disease and Domestic Medical Screening Guidance for Newly Arrived Individuals Under a Humanitarian-Based Immigration Status: A Call for Action
Nelson Iván Agudelo Higuita et al.
Volume/Issue:
Volume 107: Issue 5
Article Category: Perspective
DOI: https://doi.org/10.4269/ajtmh.22-0309

Articles

Open access

An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon
Jérôme Ateudjieu et al.
Volume/Issue: Volume 107: Issue 5
Article Category: Research Article
DOI: https://doi.org/10.4269/ajtmh.22-0462

COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variant—Zambia, December 2021
Country-Level Governance Indicators as Predictors of COVID-19 Morbidity, Mortality, and Vaccination Coverage: An Exploratory Global Analysis
Mahdi Baghbanzadeh et al.
Volume/Issue: Volume 107: Issue 5
Article Category: Research Article
DOI: https://doi.org/10.4269/ajtmh.22-0107

Measles Vaccination Immunogenicity and Association with Caste in Chandigarh, India
Abram L. Wagner et al.
Volume/Issue: Volume 107: Issue 5
Article Category: Short Report

Annals of Internal Medicine
November 2022   Volume 175, Issue 11
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 313  December 2022
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 03 Dec 2022)
[No new digest content identified]

BMJ Global Health
November 2022 - Volume 7 - 11
https://gh.bmj.com/content/7/11
[Reviewed earlier]

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 03 Dec 2022)

Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades
The timing of the launch of a new drug is an important factor that determines access for patients. We evaluated patient access to pharmaceuticals in 30 European markets over the past two decades.
BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 03 Dec 2022)
Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study
The drive to vaccinate large populations is nowadays the main instrument for combating the pandemic and preventing serious disease and death. However, breakthrough infection (post-vaccination infection) still ...
Authors: Sihem Ben Fredj, Rim Ghammem, Nawel Zammit, Amani Maatouk, Nihel Haddad, Nouha Haddad, Manel Kachroudi, Senda Rebai, Hafsia Laadhari, Mohamed Mizouni Ghodhbani, Jihen Maatoug and Hassen Ghannem
Citation: BMC Infectious Diseases 2022 22:894
Content type: Research Published on: 28 November 2022

Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7 M people
Our study examines if SARS-CoV-2 infections varied by vaccination status, if an individual had previously tested positive and by neighbourhood socioeconomic deprivation across the Delta and Omicron epidemic wa...
Authors: Mark A. Green, Daniel J. Hungerford, David M. Hughes, Marta Garcia-Fiñana, Lance Turtle, Christopher Cheyne, Matthew Ashton, Gary Leeming, Malcolm G. Semple, Alex Singleton and Iain Buchan
Citation: BMC Infectious Diseases 2022 22:889
Content type: Research Published on: 26 November 2022

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 03 Dec 2022)
Perceptions, attitudes, and willingness of the public in low- and middle-income countries of the Arab region to participate in biobank research
Authors: Mamoun Ahram, Fatma Abdelgawad, Samar Abd ElHafeez, Ahmed Samir Abdelhafiz, Maha Emad Ibrahim, Alya Elgamri, Zeinab Mohammed, Karima El-Rhazi, Eman Elshebaie, Ehsan Gamel, Manal Shahouri, Nada Taha Mostafa, Latifa Adarmouch and Henry Silverman
Content type: Research 1 December 2022

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 03 Dec 2022)
[No new digest content identified]
The determinants of immunization coverage among children aged between 12 and 35 months: a nationwide cross-sectional study in Lao People’s Democratic Republic

Immunization is one of the most important public health interventions for reducing morbidity and mortality in children. However, factors contributing to low immunization coverage are not fully understood in th...

Authors: Yasunori Ichimura, Naoki Yanagisawa, Moe Moe Thandar, Chansay Pathammavong, Kongxay Phounphenghuk, Phonethipsavanh Nousanthong, Chankham Tengbriacheu, Bouaphane Khampaphonghane, Lauren Elizabeth Franzen-Sassanpour, Tae Un Yang, Hendrikus Raaijmakers, Tomomi Ota, Kenichi Komada, Masahiko Hachiya and Shinsuke Miyano

Citation: BMC Public Health 2022 22:2259
Content type: Research Published on: 3 December 2022

COVID-19 in Europe: from outbreak to vaccination

COVID-19 is a pandemic of unprecedented proportions in recent human history. To date, the world has paid a high toll in terms of human lives lost, and on economic, financial, and social repercussions. In Europ...

Authors: Paula Vicente and Abdul Suleman
Citation: BMC Public Health 2022 22:2245
Content type: Research Published on: 2 December 2022

Improving community coverage of Japanese encephalitis vaccination: lessons learned from a mass campaign in Battambang Province, Cambodia

A mass Japanese encephalitis (JE) immunization campaign for children aged 9 months through 12 years was conducted in 2013 in Battambang province, western Cambodia. Vaccinators working at almost 2,000 immunizat...

Authors: Michael C. Thigpen, Svay Sarath, Sann Chan Soeung, Ork Vichit, Paul Kitsutani, Hardeep Sandhu, Christopher Gregory, Marc Fischer, Chheng Morn and Susan L. Hills
Citation: BMC Public Health 2022 22:2244
Content type: Research in practice Published on: 1 December 2022

Factors associated with COVID-19 booster vaccine willingness among migrants from the Eastern Mediterranean living in Australia: a cross-sectional study

Migrants have been disproportionally affected by COVID-19 in Australia. Vaccination against COVID-19 is a key pillar of Australia’s public health response, but little is known about the willingness to receive ...

Authors: Keeley Allen, Stephen B. Lambert, Aidan Yuen and Davoud Pourmarzi
Citation: BMC Public Health 2022 22:2205
Content type: Research Published on: 28 November 2022
Assessing core capacities for addressing public health emergencies of international concern at designated points of entry in Cameroon during the COVID-19 Pandemic

Points of Entry (POEs) are at the frontline for prevention, detection and response to international spread of diseases. The objective of this assessment was to ascertain the current level of existing Internati...

Authors: Viviane Fossouo Ndoungué, Arouna Njayou Ngapagna, Serge Agbo Kouadio, Raoul Djinguebey, Oumarou Gnigninanjouena, Sara Eyangoh, Georges Nguefack-Tsague, Hugues C. Nana Djeunga and Omer Njajou

Citation: BMC Public Health 2022 22:2197
Content type: Research Published on: 28 November 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 03 Dec 2022)
[No new digest content identified]

BMJ Evidence-Based Medicine
December 2022 - Volume 27 - 6
https://ebm.bmj.com/content/27/6
[Reviewed earlier]

BMJ Open
November 2022 - Volume 12 - 11
https://bmjopen.bmj.com/content/12/11
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 100(12); 2022 Dec 1
https://www.ncbi.nlm.nih.gov/pmc/issues/422466/

Editorials
Global research priorities for urban health
Nathalie Roebbel, Thiago Herick de Sa, Maria Neira, Etienne Krug
Bull World Health Organ. 2022 Dec 1; 100(12): 750–750A. Published online 2022 Dec 1.
doi: 10.2471/BLT.22.289135

Research
Prevention of mother-to-child transmission of HIV at the second immunization visit: a cross-sectional study, Burkina Faso
Béninwendé Leticia Delphine Sakana, Anais Mennecier, Paulin Fao, Souleymane Tassembedo, Jean-Pierre Moles, Dramane Kania, Ajani Ousmane Taofiki, Franck Edgar Kadeba, Ibrahima Diallo, Sabrina Eymard-Duvernay, Morgana D’Ottavi, Nicolas Meda, Beatriz Mosqueira, Philippe Van de Perre, Nicolas Nagot, on behalf of the ANRS 12388 PREVENIR-PEV Study Group
Systematic Reviews

**Tuberculosis care models for children and adolescents: a scoping review**
Courtney M Yuen, Daria Szkwarko, Melanie M Dubois, Shumail Shahbaz, Katharine A Yuengling, Michael E Urbanowski, Paul A Bain, Annemieke Brands, Tiziana Masini, Sabine Verkuijl, Kerri Viney, Yael Hirsch-Moverman, Hamidah Hussain

Cell
Nov 23, 2022 Volume 185 Issue 24 p4465-4674
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
Volume 48, Issue 6 Pages: 881-1137 November 2022
https://onlinelibrary.wiley.com/toc/13652214/current
**Special Issue: The Pervasive Effects of COVID-19 on Children: A Global Perspective**
Issue Edited by: Jan William Gorter, Evelyn Culnane, Lyndal Hickey, Mark Ferro, Tony Okely
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 112, Issue 5 Pages: 917-1130 November 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

Clinical Therapeutics
November 2022 Volume 44 Issue 11 p1427-1548
http://www.clinicaltherapeutics.com/current
[New issue; No digest content identified]

Clinical Trials
Volume 19 Issue 6, December 2022
https://journals.sagepub.com/toc/ctja/19/6
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 03 Dec 2022]
[No new digest content identified]

Contemporary Clinical Trials
Volume 122 November 2022
The CRISPR Journal
Volume 5, Issue 5 / October 2022
https://www.liebertpub.com/toc/crispr/5/5

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
Genetic, Social, and Lifestyle Drivers of Healthy Aging and Longevity
Authors (first, second and last of 4)
Patricia Alejandra Castruita
Stefanie Danielle Piña-Escudero
Jennifer S. Yokoyama
Content type: Clinical Genetics (U Fairbrother, Section Editor)
Published: 26 September 2022
Pages: 25 - 34

Current Opinion in Infectious Diseases
December 2022 - Volume 35 - Issue 6
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current

Developing World Bioethics
Volume 22, Issue 4  Pages: 181-299  December 2022
https://onlinelibrary.wiley.com/toc/14718847/current
EDITORIAL
Counting the costs of the global north's COVID-19 policies: Lives vs life years
Udo Schuklenk
Pages: 183-184
First Published: December 2022
ORIGINAL ARTICLES

Community engagement in genomic research: Proposing a strategic model for effective participation of indigenous communities
Olubunmi Ogunrin, Mark Gabbay, Kerry Woolfall, Lucy Frith
Pages: 189-202
Comparison of COVID-19 studies registered in the clinical trial platforms: A research ethics analysis perspective
Banu Buruk, Muberra Devrim Guner, Perihan Elif Ekmekci, Aksuyek Savas Celebi
Pages: 217-230
First Published: 13 September 2021

ORIGINAL ARTICLES
The proxy dilemma: Informed consent in paediatric clinical research - a case study of Thailand
Sheila Varadan, Salin Sirinam, Kriengsak Limkittikul, Phaik Yeong Cheah
Pages: 288-297
First Published: 24 January 2022
ROUNDTABLE: VULNERABLE COMMUNITIES, FUTURE GENERATIONS, AND POLITICAL REPRESENTATION IN CLIMATE POLICY AND PRACTICE

... This roundtable collection is motivated by the following question: How can the voices of vulnerable communities and future generations be adequately and fairly represented within climate change policy and practice? The contributions address this question from several perspectives. Simon Caney focuses on global governance institutions to protect the interests of future generations, considering specific proposals and asking what criteria should be used to evaluate them. Stephen Gardiner’s essay builds on his previous work calling for a global constitutional convention, elaborating on the proposal and addressing objections to it. Colin Hickey argues that it is necessary to consider more informal modes of representing vulnerable communities and future generations, such as through grassroots organizations. In our contribution, we argue that the interests of future generations are best represented in deliberations around climate policy and practice by those already most vulnerable to the impacts of climate change. Marco Grix and Krushil Watene’s essay argues that the representation of climate-vulnerable communities and future generations—in particular, Indigenous peoples—must ensure the protection of the complex network of social practices that guide how vulnerable communities respond to climate change...
Expert Review of Vaccines
Vol 21 (11) 2022
https://www.tandfonline.com/toc/ierv20/current

Foreign Affairs
Volume 101, Number 5   September/October 2022
https://www.foreignaffairs.com/issues/2022/101/5

Forum for Development Studies
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current

Genetics in Medicines
Volume 24, Issue 11  Pages A1-A8, 2211-2418 (November 2022)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/11

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 03 Dec 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList

Global Health: Science and Practice (GHSP)
Vol. 10, No. 5  October 31, 2022
http://www.ghspjournal.org/content/current

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 03 Dec 2022]
[No new digest content identified]

**Global Public Health**  
Volume 17, Issue 11 (2022)  
[Reviewed earlier]

**Globalization and Health**  
http://www.globalizationandhealth.com/  
[Accessed 03 Dec 2022]  
[No new digest content identified]

**Health and Human Rights**  
Volume 24, Issue 1, June 2022  
[Reviewed earlier]

**Health Economics, Policy and Law**  
Volume 17 - Issue 4 - October 2022  
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue  
[Reviewed earlier]

**Health Policy and Planning**  
Volume 37, Issue 9, November 2022  
https://academic.oup.com/heapol/issue/37/9  
[Reviewed earlier]

**Health Research Policy and Systems**  
http://www.health-policy-systems.com/content  
[Accessed 03 Dec 2022]  
Ethics of participation and social inclusion of older persons in research: lessons learned from the COVID-19 pandemic in Singapore  
The COVID-19 pandemic brought about safe distancing measures that are unprecedented. This article details the impact of the pandemic across research studies involving older persons in Singapore, and assesses t...  
Authors: Ad Maulod, Sasha Rouse, Atiqah Lee, Malcolm Ravindran, Hazirah Mohamad, Veronica Goh, Diyana Azman, Lian Leng Low, Rahul Malhotra and Angelique Chan  
Citation: Health Research Policy and Systems 2022 20(Suppl 1):126  
Content type: Commentary  
Published on: 29 November 2022

Impact of good governance, economic growth and universal health coverage on COVID-19 infection and case fatality rates in Africa
The coronavirus disease 2019 (COVID-19) pandemic has disrupted lives across all countries and communities. It significantly reduced the global economic output and dealt health systems across the world a seriou...

Authors: Bereket Gebremichael, Alemayehu Hailu, Mekitew Letebo, Etsub Berhanesilassie, Arega Shumetie and Sibhatu Biadgilign
Citation: Health Research Policy and Systems 2022 20:130
Content type: Research Published on: 28 November 2022

Human Gene Therapy
Volume 33, Issue 21-22 / November 2022
https://www.liebertpub.com/toc/hum/33/21-22
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Nov 08, 2022 Volume 55 Issue 11 p1967-2210
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 03 Dec 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 03 Dec 2022]
Sustainable strategies for Ebola virus disease outbreak preparedness in Africa: a case study on lessons learnt in countries neighbouring the Democratic Republic of the Congo
Authors: Caroline S. Ryan, Marie-Roseline D. Belizaire, Miriam Nanyunja, Olushayo Oluseun Olu, Yahaya Ali Ahmed, Anderson Latt, Matthew Tut Kol, Bertrand Bamuleke, Jayne Tusiime, Nadia Nsabimbona, Ishata Conteh, Shamiso Nyashanu, Patrick Otim Ramadan, Solomon Fisseha Woldetsadik, Jean-Pierre Mulunda Nkata, Jim T. Ntwari...
Content type: Case Study 2 December 2022

**International Health**  
Volume 14, Issue 6, November 2022  
https://academic.oup.com/inthealth/issue/14/6  
[Reviewed earlier]

**International Human Rights Law Review**  
Volume 11 (2022): Issue 1 (Jun 2022)  
https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml  
*Table of Contents*  
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**  
Vol 9, No 11 (2022) November 2022  
[New issue; No digest content identified]

**International Journal of Epidemiology**  
Volume 51, Issue 5, October 2022  
https://academic.oup.com/ije/issue  
[Reviewed earlier]

**International Journal of Human Rights in Healthcare**  
Volume 15 Issue 3, 2022  
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3  
*Special Issue: Children, young people and their international human right to healthcare*  
[Reviewed earlier]

**JAMA**  
November 22/29, 2022, Vol 328, No. 20, Pages 1993-2078  
https://jamanetwork.com/journals/jama/currentissue  
[Reviewed earlier]

**JAMA Pediatrics**  
November 2022, Vol 176, No. 11, Pages 1061-1156  
https://jamanetwork.com/journals/jamapediatrics/currentissue  
[Reviewed earlier]

**JBI Evidence Synthesis**
Journal of Adolescent Health
November 2022  Volume 71  Issue 5  p521-654
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 75 (2022)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 6, December 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-6
[Reviewed earlier]

Journal of Development Economics
Volume 159  November 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 5, December 2022
http://journals.sagepub.com/toc/jre/current
Ethical Issues using Digital Surveillance Technologies in Research
[Reviewed earlier]

Journal of Epidemiology & Community Health
November 2022 - Volume 76 - 11
https://jech.bmj.com/content/76/11
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 3  Pages: 181-314  September 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]
Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current
Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 4, November 2022
https://muse.jhu.edu/issue/48371
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 5, October 2022
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 20, 2022 _ Issue 4
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 226, Issue 10, 15 November 2022
https://academic.oup.com/jid/issue/226/10
[New issue; No digest content identified]

Journal of International Development
Volume 34, Issue 8 Pages: 1453-1648 November 2022
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
November 2022 - Volume 48 - 11
http://jme.bmj.com/content/current
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]
Vaccine management practices among healthcare workers in Morogoro, Tanzania: a cross-sectional study

Effective vaccine management is essential to maintain the quality of vaccines, minimise wastages, and prevent missed opportunities for vaccination at service delivery points.

Authors: Bonaventura Nestory, Mackfallen Anasel, Jean Baptiste Nyandwi and Domina Asingizwe

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:95

Content type: Research Published on: 30 November 2022
Journal of Travel Medicine
Volume 29, Issue 7, October 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96 Number 18 September 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Dec 03, 2022 Volume 400 Number 10367 p1899-2006
https://www.thelancet.com/journals/lancet/issue/current
Articles
Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series
John P Thornhill, et al. on behalf of the Share-Net writing group

The Lancet Child & Adolescent Health
Nov 2022 Volume 6 Number 11 p747-828, e22-e23
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Nov 2022 Volume 4 Number 11 e765-e849
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Nov 2022 Volume 22 Number 11 p1513-1648, e310-e347
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Nov 2022 Volume 7 Number 11 e885-e982
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Nov 2022 Volume 10 Number 11 p1009-1098, e94-e106
https://www.thelancet.com/journals/lanres/issue/current
In praise of research in fundamental biology

Science funders must remember the value of addressing the intrinsic biological questions that help to explain the natural world.
**Nature Human Behaviour**
Volume 6 Issue 11, November 2022
https://www.nature.com/nathumbehav/volumes/6/issues/11
[Reviewed earlier]

**Nature Medicine**
Volume 28 Issue 11, November 2022
https://www.nature.com/nm/volumes/28/issues/11
[Reviewed earlier]

**Nature Reviews Drug Discovery**
Volume 21 Issue 11, November 2022
https://www.nature.com/nrd/volumes/21/issues/11
[Reviewed earlier]

**Nature Reviews Genetics**
Volume 23 Issue 11, November 2022
https://www.nature.com/nrg/volumes/23/issues/11
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 22 Issue 11, November 2022
https://www.nature.com/nri/volumes/22/issues/11
[Reviewed earlier]

**New England Journal of Medicine**
December 1, 2022  Vol. 387 No. 22
https://www.nejm.org/toc/nejm/medical-journal

**Perspective**
*It Ain’t Over Till It’s Over…but It’s Never Over — Emerging and Reemerging Infectious Diseases*
A.S. Fauci
[See Featured Journal Content above for detail]

**npj Vaccines**
https://www.nature.com/npjvaccines/
[Accessed 03 Dec 2022]

**Article  Open Access**
Published: 03 December 2022
*BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children*
Yannic C. Bartsch, et al.
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Research Article | published 01 Dec 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004136
COVID-19 vaccine acceptability, and uptake among people living with HIV in Uganda
Richard Muhindo, Stephen Okoboi, Agnes Kiragga, Rachel King, Walter Joseph Arinaitwe, Barbara Castelnuovo
Research Article | published 02 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278692

Attitudes towards Monkeypox vaccination and predictors of vaccination intentions among the US general public
Maike Winters, Amyn A. Malik, Saad B. Omer
Research Article | published 01 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278622

Managing COVID-19 in an Australian designated isolation facility: Implications for current and future healthcare crises based on in-depth interviews
Helen M. Achat, Rakhi Mittal, Joanne M. Stubbs, Nicky Gilroy, Suzanne K. Schindeler, Ramon Z. Shaban, Thomas Solano
Research Article | published 01 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278479

Factors influencing human papillomavirus school-based immunization in Alberta: A mixed-methods study protocol
Study Protocol | published 01 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278472

Perception and willingness to accept COVID-19 Vaccines: A cross-sectional survey of the general population of Sokoto State, Nigeria
Oche Mansur Oche, Habibullah Adamu, Musa Yahaya, Hudu Garba Illo, Abdulaziz Mohammad Danmadami, Adamu Ijapa, Asmau Mohammad Wali, Hamza Yusuf, Hafsat Muhammad, Abba Aji
Research Article | published 01 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278332

A systematic review and meta-analysis of the prevalence of caregiver acceptance of malaria vaccine for under-five children in low-income and middle-income countries (LMICs)
Sahabi Kabir Sulaiman, Muhammad Sale Musa, Fatimah Ismail Tsiga-Ahmed, Farouq Muhammad Dayyab, Abdulwahab Kabir Sulaiman, Abdulaziz Tijjani Bako
Research Article | published 01 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0278224

Hesitation about coronavirus vaccines in healthcare professionals and general population in Spain
Francesc Saigí-Rubió, Hans Eguia, Albert Espelt, Salvador Macip, Marina Bosque-Prous
Research Article | published 01 Dec 2022 PLOS ONE
Community engagement to increase vaccine uptake: Quasi-experimental evidence from Islamabad and Rawalpindi, Pakistan
Mujahid Abdullah, Taimoor Ahmad, Twangar Kazmi, Faisal Sultan, Sabeen Afzal, Rana Muhammad Safdar, Adnan Ahmad Khan
Research Article | published 01 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274718

Can a supranational medicines agency restore trust after vaccine suspensions? The case of Vaxzevria
Andrea Albanese, Francesco Fallucchi, Bertrand Verheyden
Research Article | published 30 Nov 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0277554

A deliberative public engagement study on heritable human genome editing among South Africans: Study results
Donrich Thaldar, Bonginkosi Shozi, Michaela Steytler, Gill Hendry, Marietjie Botes, Ntokozo Mnyandu, Meshandren Naidoo, Siddharthiya Pillay, Magda Slabbert, Beverley Townsend
Research Article | published 28 Nov 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275372

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 03 Dec 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
December 6, 2022 | vol. 119 | no. 49
Research Article November 29, 2022Coronavirus (COVID-19)
Long-term benefits of nonpharmaceutical interventions for endemic infections are shaped by respiratory pathogen dynamics
Rachel E. Baker, Chadi M. Saad-Roy,[...] Bryan T. Grenfell
Significance
Nonpharmaceutical interventions, such as mask wearing, introduced to limit the spread of COVID-19 have proved effective at reducing cases of other respiratory diseases. A key public health question is whether these interventions could be introduced long term to limit outbreaks of diseases such as influenza. Here, we use epidemic models to show that the effect of mask wearing on endemic disease is likely short lived. Over longer time horizons, outbreaks may return while interventions are in place, as population immunity decreases.

Prehospital & Disaster Medicine
Volume 37 - Supplement S2 - November 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
Abstracts of World Health Organization Emergency Medical Teams Global Meeting 2022

Preventive Medicine
Volume 164 November 2022
[Reviewed earlier]

Proceedings of the Royal Society B
30 November 2022 Volume 289 Issue 1987
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 212 Pages 1-110 (November 2022)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 6, November/December 2022
https://journals.sagepub.com/toc/phrg/137/6
[Reviewed earlier]

Qualitative Health Research
Volume 32 Issue 13, November 2022
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 18 Issue 4, October 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 03 Dec 2022]
[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**
https://www.paho.org/journal/en
*Selected Articles*
[No new digest content identified]

**Risk Analysis**
Volume 42, Issue 10  Pages: 2125-2343  October 2022
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

**Risk Management and Healthcare Policy**
[Accessed 03 Dec 2022]
*Original Research*
**Understanding the Attitudes and Willingness of Adult Chinese Patients with Rheumatic Diseases Towards COVID-19 Vaccination**
*Risk Management and Healthcare Policy* 2022, 15:2269-2281
Published Date: 1 December 2022

**Science**
Volume 378| Issue 6622| 25 Nov 2022
https://www.science.org/toc/science/current
*Policy Forum*
**Legal reform to enhance global text and data mining research**
BY Sean M. Fiil-Flynn, et al.
01 Dec 2022: 951-953
Outdated copyright laws around the world hinder research

*Research Articles*
**Vaccination induces HIV broadly neutralizing antibody precursors in humans**
BY David J. Leggat, et al.
02 Dec 2022
Results from a phase 1 clinical trial for a broadly neutralizing antibody germline-targeting HIV vaccine in humans are reported.

**Science and Engineering Ethics**
Volume 28, issue 6, December 2022
[Reviewed earlier]
For insights into the real world, consider real-world data
BY Sana Raoof, Razelle Kurzrock
30 Nov 2022
Real world evidence is a pragmatic complement to, and sometimes a replacement for, randomized control clinical trials in oncology.

Social Science & Medicine
Volume 313 November 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 03 Dec 2022]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 43, issue 5-6, December 2022
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 50 November–December 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 11 Pages: i-iv, 941-1023 November 2022
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 40, Issue 48 Pages 6893-7010 (15 November 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/48
Selected Content
Discussion No access
Preferential recommendations for vaccines: Time for a structured, transparent process
Kelly L. Moore, Litjen Tan
Pages 6893-6894

Research article  Full text access
Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama
Marie C.D. Stoner, David Tweedy, Maria G. Leonora Comello, Christina Toval, ... Lisa B. Hightow-Weidman
Pages 6908-6916

Research article  Full text access
Where are children ages 5–17 years receiving their COVID-19 vaccinations? Variations over time and by sociodemographic characteristics, United States
Tammy A. Santibanez, Carla L. Black, Tara M. Vogt, Kevin Chatham-Stephens, ... James A. Singleton
Pages 6917-6923

Research article  Open access
Rashmi Nayar, Balasubramanyam Pattath, Nivedita Mantha, Sisir Debnath, Sarang Deo
Pages 6924-6930

Research article  Full text access
The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study
Hanqing He, Yao Zhu, Mingjuan Jin, Yang Zhou, ... Kun Chen
Pages 6956-6962

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 03 Dec 2022]

Monkeypox Disease (MPOX) Perceptions among Healthcare Workers versus General Population during the First Month of the WHO Alert: Cross-Sectional Survey in Saudi Arabia
by Mohamad-Hani Temsah
Vaccines 2022, 10(12), 2071; https://doi.org/10.3390/vaccines10122071 (registering DOI) - 03 Dec 2022

Abstract
Background: Monkeypox disease (MPOX) recently re-emerged in May 2022, causing international outbreaks in multiple non-endemic countries. This study demonstrates a novel comparison between the knowledge and perceptions of Saudi healthcare workers (HCWs) and the general public regarding MPOX. Methods: An online survey, conducted [...]

Open Access  Review
Global Policy to Reduce the Incidence of Infection Spreading in Non-Vaccinated Healthcare Workers: A Literature Review
by Cristina Ferrari
Vaccines 2022, 10(12), 2058; https://doi.org/10.3390/vaccines10122058 - 30 Nov 2022
Abstract
Healthcare workers (HCWs) are at increased risk of Sars-CoV-2 infection because of their occupational exposure. Moreover, they can be a vehicle for the virus transmission among patients. The vaccination of healthcare personnel against COVID-19 is crucial in fighting the spread of SARS-CoV-2 infection, [..]

Open Access Article
Understanding Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs
by Ashly E. Jordan
Abstract
Background: People who use drugs (PWUD) are at high risk for COVID-19 infection, morbidity, and mortality. COVID-19 vaccines are safe and effective at reducing serious illness and death from COVID-19. There are sparse data on the perceptions and willingness of PWUD to receive […]

Open Access Review
Moving towards Digitising COVID-19 Vaccination Certificate: A Systematic Review of Literature
by Jonathan Kissi
Vaccines 2022, 10(12), 2040; https://doi.org/10.3390/vaccines10122040 - 29 Nov 2022
Abstract
The coronavirus pandemic is the greatest crisis of our time, having claimed over 2 million lives and shocking the global economy. Scientists and governments have suggested the idea of a digital COVID-19 certificate, to identify vaccinated persons easily. This paper assesses the positions […]

Value in Health
December 2022 Volume 25 Issue 12 p1925-2080
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

:::::::

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

:::::::

Pre-Print Servers
Infant Vaccination Does Not Predict Increased Infant Mortality Rate: Correcting Past Misinformation
Ella Nysetvold, Tess Mika, Weston Elison, Daniel Garrett, Justin Hunt, Inori Tsuchiya, Steven William Brugger, Mary F Davis, Samuel H Payne, Elizabeth Gibbons Bailey
medRxiv 2021.09.03.21263082; doi: https://doi.org/10.1101/2021.09.03.21263082

The imprinting effect of COVID-19 vaccines: an expected selection bias in observational studies
Susana Monge, Roberto Pastor-Barriuso, Miguel A. Hernán
medRxiv 2022.11.30.22282923; doi: https://doi.org/10.1101/2022.11.30.22282923

Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general population
Jia Wei, Philippa C. Matthews, Nicole Stoesser, John N Newton, Ian Diamond, Ruth Studley, Nick Taylor, John I Bell, Jeremy Farrar, Jaison Kolenchery, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, Koen B. Pouwels, David W. Eyre, the COVID-19 Infection Survey team
medRxiv 2022.11.29.22282916; doi: https://doi.org/10.1101/2022.11.29.22282916

Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: a study protocol for an Expanded Access Programme
Josephine Bourner, Festus Devincy Redji Mbenga, Christian Noël Malaka, Jake Dunning, Amanda Rojek, Emmanuel Fandema, Peter Horby, Yap Boum II, Emmanuel Nakouné, Piero Olliaro
medRxiv 2022.11.28.22282846; doi: https://doi.org/10.1101/2022.11.28.22282846

The influence of COVID-19 risk perception and vaccination status on the number of social contacts across Europe: insights from the CoMix study
James Wambua, Neilshan Loedy, Christopher I Jarvis, Kerry LM Wong, Christel Faes, Rok Grah, Bastian Prasse, Frank Sandmann, Rene Niehus, Helen Johnson, W. John Edmunds, Philippe Beutels, Niel Hens, Pietro Coletti
medRxiv 2022.11.25.22282676; doi: https://doi.org/10.1101/2022.11.25.22282676

The importance of vaccinated individuals to population-level evolution of pathogens
Maria A. Gutierrez, Julia R. Gog
medRxiv 2022.11.29.22282822; doi: https://doi.org/10.1101/2022.11.29.22282822
Association of childhood vaccination with family planning, healthcare access, and women education: analysis of Nepal, Senegal and Zambia
Francisco Castillo-Zunino, Kyra A Hester, Pinar Keskinocak, Dima Nazzal, Matthew C Freeman

Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study
Chaelin Kim, Marianne Holm, Isabel Frost, Mateusz Hasso-Agopsowicz, Kaja Abbas
medRxiv 2022.05.08.22274821; doi: https://doi.org/10.1101/2022.05.08.22274821

Defining the Critical Educational Components of Informed Consent for Genetic Testing: Views of US-Based Genetic Counselors and Medical Geneticists
medRxiv 2022.11.22.22282640; doi: https://doi.org/10.1101/2022.11.22.22282640

Enhanced cholera surveillance as a tool for improving vaccination campaign efficiency
Hanmeng Xu, Kaiyue Zou, Kirsten E. Wiens, Espoir Bwenge Malembaka, Andrew S. Azman, Elizabeth C. Lee
medRxiv 2022.11.25.22282776; doi: https://doi.org/10.1101/2022.11.25.22282776

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLifeSciences
[Accessed 03 Dec 2022]
[Provider Filter: OSF Pre-prints  Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

Human judgment forecasts of human monkeypox transmission and burden in non-endemic countries
Thomas McAndrew
Maimuna S. Majumder
Andrew A. Lover
Srini Venkatramanan
Paolo Bocchini
Allison Codi
Tamay Besiroglu
David Braun
Gaia Dempsey
Sam Abbott
+3
Last edited: Dec 2, 2022 UTC
Life Sciences Immunology and Infectious Disease
Background: An increase in reported human infections by the monkeypox virus (MPXV) has been observed in multiple non-endemic countries. Forecasts of transmission and disease burden associated with MPXV can support public health decision making. However, historical data that can be used to train comp ...
OSF Preprints
An Improved Peer-Review System to Compensate for Scientific Misconduct in Health-Sensitive Topics
Alessandro Rovetta
Rossana Garavaglia
Alessandro Vitale
Behailu Terefe Tesfaye
Vincenzo Accurso
Last edited: Dec 1, 2022 UTC
*Medicine and Health Sciences Public Health*

With this letter, we do ask the scientific community to take a clear position and make itself heard with a stentorian voice to protect public health from ethical misconduct. This renewal would lead not only to direct benefits to the research but also to the public image of the whole scientific world...

Warmth and competence perceptions of key protagonists are associated with containment measures during the COVID-19 pandemic: Evidence from 35 countries
Maria-Therese Friehs
Patrick Kotzur
Christine Kraus
Moritz Schemmerling
Jessica Alina Herzig
Adrian Stanciu
Sebastian Dilly
Lisa Hellert
Doreen Hübner
Anja Rückwardt
+56
Last edited: Nov 30, 2022 UTC
*Social and Behavioral Sciences Psychology Social Psychology*

It is crucial to understand why people comply with measures to contain viruses and their effects during pandemics. We provide evidence from 35 countries (Ntotal = 12,553) from six continents during the COVID-19 pandemic (between 2021 and 2022) obtained via cross-sectional surveys that the social per...

Wellcome Open Research  [to 03 Dec 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 03 Dec 2022]
*Selected Research*
Systematic Review metrics AWAITING PEER REVIEW
Outdoor air pollution impacts chronic obstructive pulmonary disease deaths in South Asia and China: a systematic review and meta-analysis  [version 1; peer review: awaiting peer review]
Bellipady Shyam Prasad Shetty, George D’souza, Mahesh Padukudru Anand, Meghna Rai Prasad
Peer Reviewers Invited
Funder
Research Article metrics
Revised

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study [version 3; peer review: 1 approved, 1 approved with reservations]
Peer Reviewers Shelley Lees; Cathrine Slack
Funders
Wellcome Trust
COVID-19 Therapeutics Accelerator
LATEST VERSION PUBLISHED 01 Dec 2022

Abstract
Background: The COPCOV study (chloroquine/ hydroxychloroquine prevention of coronavirus disease), which started recruitment in April 2020, is a multi-country double-blind, randomised, placebo-controlled trial which is being conducted in healthcare facilities involved in COVID-19 case management. Participants are staff employed in facilities managing people with proven or suspected COVID-19. As part of the study, we conducted a series of engagement sessions. The aims were to assess the feasibility of the study, to identify context-specific ethical issues, to understand possible concerns, to fine tune research procedures and to refine the COPCOV information materials.

Methods: The COPCOV study was approved by relevant institutional review boards. The sessions described in this paper were part of the study. We conducted a series of engagement sessions, each involving a short presentation of the study, a section where attendees were asked to express their willingness to participate in such a study, which information they would need to change their view and an open Q&A section. Answers were transcribed and coded into themes by two independent investigators. Themes were derived from the data. They complemented other site-specific engagement, communication, and public relation activities such as press releases and websites.

Results and conclusions: From 16th March 2020 to 20th January 2021, 12 engagement sessions were conducted in Thailand, Laos, Vietnam, Nepal and the UK involving 213 attendees in total. Issues raised revolved around the social value and study rationale; safety of trial medications and risk-benefit balance; study design and commitments. These sessions helped us identify concerns people had, which helped us refine information materials as well as complement site feasibility assessments. Our experience strongly supports the use of participatory practices prior to conducting clinical trials.

Study Protocol metrics
Revised

Protocol for the Addressing the Social Determinants and Consequences of Tuberculosis in Nepal (ASCOT) pilot trial [version 2; peer review: 1 approved, 1 approved with reservations]
Bhola Rai, Kritika Dixit, Raghu Dhital, Poonam Rishal, Suman Chandra Gurung, Puskar Raj Paudel, Gokul Mishra, Laura Bonnett, Noemia Siqueira-Filha, Mukti Nath Khanal, Knut Lonnroth, S Bertel Squire, Maxine Caws, Tom Wingfield
Peer Reviewers Winters Muttamba; Louise Marston
Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 2; peer review: 2 approved with reservations]
Noha Abdelgawad, Maxwell Chirehwa, Charlotte Schutz, David Barr, Amy Ward, Saskia Janssen, Rosie Burton, Robert J. Wilkinson, Muki Shey, Lubbe Wiesner, Helen McIlleron, Gary Maartens, Graeme Meintjes, Paolo Denti
Peer Reviewers Oscar Della Pasqua; Jotam Pasipanodya

Funders
Wellcome Trust
Medical Research Council

REVISED PHARMACOKINETICS OF ANTITUBERCULAR DRUGS IN PATIENTS HOSPITALIZED WITH HIV-ASSOCIATED TUBERCULOSIS: A POPULATION MODELING ANALYSIS [VERSION 2; PEER REVIEW: 2 APPROVED WITH RESERVATIONS]

Noha Abdelgawad, Maxwell Chirehwa, Charlotte Schutz, David Barr, Amy Ward, Saskia Janssen, Rosie Burton, Robert J. Wilkinson, Muki Shey, Lubbe Wiesner, Helen McIlleron, Gary Maartens, Graeme Meintjes, Paolo Denti
Peer Reviewers Oscar Della Pasqua; Jotam Pasipanodya

Funders
Wellcome Trust
NRF
Francis Crick Institute
South African Medical Research Council through its TB and HIV Collaborating Centres Programme with funds received from the National Department of Health
National Institutes of Health
EDCTP
South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa

Research Article metrics
Revised
Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 2; peer review: 2 approved with reservations]
Noha Abdelgawad, Maxwell Chirehwa, Charlotte Schutz, David Barr, Amy Ward, Saskia Janssen, Rosie Burton, Robert J. Wilkinson, Muki Shey, Lubbe Wiesner, Helen McIlleron, Gary Maartens, Graeme Meintjes, Paolo Denti
Peer Reviewers Oscar Della Pasqua; Jotam Pasipanodya
Funders
Wellcome Trust
NRF
Francis Crick Institute
South African Medical Research Council through its TB and HIV Collaborating Centres Programme with funds received from the National Department of Health
National Institutes of Health
EDCTP
South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa
LATEST VERSION PUBLISHED 28 Nov 2022

Think Tanks

Brookings [to 03 Dec 2022]
http://www.brookings.edu/
Latest Research [Selected]
No new digest content identified

Center for Global Development [to 03 Dec 2022]
https://www.cgdev.org/
All Research [Selected]
POLICY PAPERS
Operation Warp Speed, Encore: A Case for US Leadership to Drive Market-Based Global Health Innovation
Rachel Silverman
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this...
experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...

**Chatham House**  [to 03 Dec 2022]
https://www.chathamhouse.org/
Selected Analysis, Comment
**China’s zero-COVID cannot continue, reopening is needed**
Unsure of how to loosen rules, local officials have doubled down on severe restrictions behind so much economic damage. Reopening will quell public anger.
Expert Comment - Dr Yu Jie
Senior Research Fellow on China, Asia-Pacific Programme
1 December 2022

**Feature**
**Moving medicine in Iraq: Networks fuelling everyday conflict**
A system involving doctors, pharmacists, political parties, armed groups, and businesspeople fuels corruption and conflict in a medicine supply chain which kills people every year.
29 November 2022

**CSIS**  [to 03 Dec 2022]
https://www.csis.org/
Selected Reports, Events
No new digest content identified.

**Kaiser Family Foundation**  [to 03 Dec 2022]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

**ODI  [Overseas Development Institute]**  [to 03 Dec 2022]
Publications
**Reproductive justice, sexual rights and bodily autonomy in humanitarian action: what a justice lens brings to crisis response**
30 November 2022
Working papers

**Pew Research Center**  [to 03 Dec 2022]
https://www.pewresearch.org/
Latest Publications short read | Nov 29, 2022
**Key findings about COVID-19 restrictions that affected religious groups around the world in 2020**
Our study analyzes 198 countries and territories and is based on policies and events in 2020, the most recent year for which data is available.

In three-in-ten or more countries in each region, religious groups defied COVID-19 health measures

Number of countries in each region where religious groups or individuals defied COVID-19 public health measures

- **14 countries**
  - Europe
  - 31% of region
- **13 countries**
  - Americas
  - 37% of region
- **6 countries**
  - Middle East-N. Africa
  - 30% of region
- **16 countries**
  - Asia-Pacific
  - 32% of region
- **20 countries**
  - Sub-Saharan Africa
  - 42% of region
- **69 total countries**


Pew Research Center

**report | Nov 29, 2022**


Nearly a quarter of countries used force to prevent religious gatherings during the pandemic; other government restrictions and social hostilities related to religion remained fairly stable.

**Rand | [to 03 Dec 2022]**

https://www.rand.org/pubs.html

*Reports, Selected Journal Articles*

*Journal Article*

**Has COVID-19 Changed How People Think About the Drivers of Health? If So, Does It Matter?**

We assessed changes in health mindset associated with the COVID pandemic and found that respondents were more likely in 2021 than in 2018 to recognize social determinants of health. This is associated with greater openness to pandemic-control measures.

Nov 29, 2022

Christopher Nelson, Laurie T. Martin, Douglas Yeung, Delia Bugliari

**Urban Institute | [to 03 Dec 2022]**
Mini-RCTs: A Tool for Program Managers to Help Identify What Works

December 2, 2022

This brief describes a tool—mini randomized controlled trials (Mini-RCTs) – to help close this evidence gap for managers of almost any public service, and at a surprisingly low cost.

Randomized controlled trials (RCTs) have been called the gold standard for identifying the impacts of public service-delivery procedures (Hariton and Locascio 2018). RCTs compare outcomes for randomly selected participants who receive a new or modified service procedure with outcomes of participants who have not received the new procedure. This process provides strong evidence on the impacts of the new procedure...

World Economic Forum  [to 03 Dec 2022]
https://agenda.weforum.org/news/
Media
No new digest content identified.

* * * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

* * * * *

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health,
human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*                  *                  *                  *
*                  *                  *                  *

*